(Q37976623)

26 August 2017

Current treatment options for metastatic head and neck cancer (English)

1 reference

26 August 2017

Katharine A R Price

1

1 reference

PubMed ID

22252884

26 August 2017

Ezra E Cohen

series ordinal

2

1 reference

26 August 2017

1 March 2012

1 reference

Current Treatment Options in Oncology

26 August 2017

1 reference

26 August 2017

13

1 reference

26 August 2017

1

1 reference

26 August 2017

35-46

1 reference

https://scigraph.springernature.com/pub.10.1007/s11864-011-0176-y

26 August 2017

0 references

cites work

Case-control study of human papillomavirus and oropharyngeal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

The p53 network in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

Human papillomavirus and survival of patients with oropharyngeal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

Docetaxel: an active drug for squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

Evaluation of gemcitabine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

Vinorelbine in pre-treated advanced head & neck squamous cell carcinoma. A phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

Platinum-based chemotherapy plus cetuximab in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0176-Y

A causal role for human papillomavirus in head and neck cancer

21 January 2018

1 reference

12 December 2020

Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial.

1 reference

12 December 2020

Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02).

1 reference

12 December 2020

Ifosfamide in the treatment of advanced or recurrent squamous cell carcinoma of the head and neck: a phase II Hoosier Oncology Group trial

1 reference

12 December 2020

Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck

1 reference

12 December 2020

A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies

1 reference

12 December 2020

Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer

1 reference

12 December 2020

Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390)

1 reference

12 December 2020

Ifosfamide and mesna for the treatment of advanced squamous cell head and neck cancer. A GETLAC study

1 reference

12 December 2020

A phase III randomised trial of cistplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group

1 reference

12 December 2020

A phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck

1 reference

12 December 2020

Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.

1 reference

12 December 2020

Pain as sign of recurrent disease in head and neck squamous cell carcinoma

1 reference

12 December 2020

Ifosfamide in advanced epidermoid head and neck cancer

1 reference

12 December 2020

An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

1 reference

12 December 2020

A phase II trial of vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

12 December 2020

10.1007/S11864-011-0176-Y

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22252884